Henan Newland Pharmaceutical Co. Ltd. A (301277) - Total Liabilities
Based on the latest financial reports, Henan Newland Pharmaceutical Co. Ltd. A (301277) has total liabilities worth CN¥236.14 Million CNY (≈ $34.55 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Henan Newland Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2020–2025)
This chart illustrates how Henan Newland Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. See Henan Newland Pharmaceutical Co. Ltd. A (301277) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Henan Newland Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Henan Newland Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CJ ENM CO. Ltd
KQ:035760
|
Korea | ₩5.22 Trillion |
|
Jiangsu Rijiu Optoelectronics Joint
SHE:003015
|
China | CN¥158.03 Million |
|
Mia Teknoloji AS
IS:MIATK
|
Turkey | TL1.99 Billion |
|
Dymatic Chemicals Inc
SHE:002054
|
China | CN¥3.43 Billion |
|
Guangzhou Pearl River Industrial Development Co Ltd
SHG:600684
|
China | CN¥842.36 Million |
|
Zevra Therapeutics Inc.
NASDAQ:ZVRA
|
USA | $136.95 Million |
|
Ningbo Daye Garden Machinery Co Ltd
SHE:300879
|
China | CN¥3.52 Billion |
|
Joyware Electronics Co Ltd
SHE:300270
|
China | CN¥230.58 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Henan Newland Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Henan Newland Pharmaceutical Co. Ltd. A market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Henan Newland Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
The table below shows the annual total liabilities of Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥228.49 Million ≈ $33.44 Million |
-15.59% |
| 2024-12-31 | CN¥270.69 Million ≈ $39.61 Million |
+69.16% |
| 2023-12-31 | CN¥160.02 Million ≈ $23.42 Million |
-8.34% |
| 2022-12-31 | CN¥174.58 Million ≈ $25.55 Million |
-33.24% |
| 2021-12-31 | CN¥261.53 Million ≈ $38.27 Million |
+25.39% |
| 2020-12-31 | CN¥208.57 Million ≈ $30.52 Million |
-- |
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naph… Read more